Peer-influenced content. Sources you trust. No registration required. This is HCN.

Eyewire+Thea Pharma Announces FDA Approval of Glaucoma Drug Iyuzeh

Iyuzeh (latanoprost ophthalmic solution), which will be offered to eyecare professionals in the US in the second half of 2023, is made without any of the preservatives often included in topical ocular treatments, such as benzalkonium chloride (BAK). Iyuzeh has consistently lowered IOP and been shown to be tolerable in numerous trials in the US and Europe. In randomized, controlled clinical studies, Iyuzeh reduced IOP by 3–8 mmHg against 4–8 mmHg by Xalatan (latanoprost ophthalmic solution) at 0.005%, which is preserved with BAK, in patients with open-angle glaucoma or ocular hypertension and mean baseline IOP of 19–24 mmHg.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form